Health Blueprint

Back to Longevity News

News summary

Cambiotics initiates first human clinical trial focused on PFAS reduction in firefighters with occupational PFAS exposure

Source: PR Newswire • Published: 03 Nov 2026, 15:47

Summarized by Masters of Longevity from PR Newswire.

A randomized, double-blind crossover trial will test probiotic 46-SL1's effect on serum PFAS.

Cambiotics initiates first human clinical trial focused on PFAS reduction in firefighters with occupational PFAS exposure
Key Takeaways
  • The trial is randomized, double-blind, placebo-controlled.
  • Seventy firefighters with occupational PFAS exposure are enrolled.
  • The study measured serum PFAS, safety, and microbiome changes.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.